08:26 AM EST, 01/13/2025 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) on Monday reported preliminary Q4 Rezdiffra net sales of $100 million to $103 million.
The company also reported preliminary yearend 2024 cash, cash equivalents, restricted cash and marketable securities of about $931 million.